DIgital Assisted MONitoring for DiabeteS - I

Diabetes Mellitus Clinical Trial

— DIAMONDS  

Official title:

A Telemedicine-based Intervention Study Involving Real-time and Anywhere Transmission of Blood Glucose Data to a Decision Supported Software-assisted Server With Web-based Analysis of Data and Medical Feedback on Metabolic Control.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01804803
• Other study ID #: DIAMONDS-I
• Status: Completed
• Phase: N/A
• Start date: September 9, 2013
• Est. completion date: November 30, 2017

Study information

• Verified date: June 2020
• Source: University of Bari
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aims to validate the clinical efficacy of a telemedicine- and web-based system platform for Self-monitoring of blood glucose (SMBG) data transmission and analysis in terms of improved metabolic control, assessed by measuring changes in HbA1c, in insulin-treated diabetic patients. The system platform involves (i.) systematic (real-time and anywhere) transmission of SMBG data to a decision supported software (DSS)-assisted server, (ii.) web-based analysis of data, and (iii.) feedback on patients and medical staff to implement metabolic control. The expected outcome is that using this telemedicine-based system with transmission of SMBG data, web-based analysis of data and medical feedback to patients and medical team will improve glucose control in insulin-treated individuals with type 1 or type 2 diabetes mellitus.

Description:

Self-monitoring of blood glucose (SMBG) is currently recommended in all type 1 diabetic patients and type 2 diabetic treated with insulin (≥4 glucose testing per day), as a tool to favor achievement of glucose control. It is still debated whether SMBG is also useful to achieve improved glucose control in non-insulin treated type 2 diabetes due to discordant results from intervention trials [Farmer AJ, 2009]. In general, it is assumed that the usefulness of SMBG is fully met when SMBG is performed in a structured manner, and both the patient and medical team make use of the SMBG results to optimize lifestyle and drug therapy; this should result in more effective control of both hyperglycemia and hypoglycemia, resulting in less glucose variability [IDF, 2009]. SMBG is currently performed by a majority of diabetic patients, including non-insulin treated type 2 patients; however, the SMGB procedure is often far from being satisfactory due to inappropriate frequency of testing, data collection and data analysis, resulting in a suboptimal impact on disease management. Thus, multiple unmet needs currently exist in the SMBG procedure, which could be resolved by (i.) implementing appropriate SMBG testing frequencies (# blood glucose (BG) tests/day-week-month); (ii.) temporally localizing BG tests with respect to fasting periods vs. meals/snacks; (iii.) improving the quality control of the SMBG procedure (use of strips, calibration, testing, data collection and analysis); (iv.) making SMBG results available for statistical and medical analyses to monitor diabetes status and adjust lifestyle and drug therapy when needed; (v.) providing the patient with appropriate feed-back driven by SMBG data analysis; and (vi.) monitoring real-time SMBG data to detect emergency situations (e.g., severe hypoglycemia, persistent hyperglycemia) to assist the patient with appropriate and timely interventions.

There is a growing body of evidence to suggest that telemedicine is an effective intervention for improving glucose control. Use of telephone contacts, video-conferencing, personal digital assistants and web-based systems offer new opportunities to bridge the gap in support for patients with diabetes between face to face visits with their health care providers. Several small-scale and non-randomized studies have found that patients exposed to telemonitoring interventions had lower HbA1c values than those without. Moreover, larger randomized controlled studies have also shown promising results. In the most comprehensive randomized comparison of telemonitoring interventions yet completed, the IDEATel study, 1,665 participants were randomized to a telemedicine unit or conventional care. At 1 year, patients in intervention group showed significantly lower HbA1c (-0.38 % p<0.01), systolic and diastolic blood pressure, (respectively, -3.4 mmHg, p= 0.001; -1.9 mmHg, p<0.001), and low density lipoprotein (LDL) cholesterol (-9.5 mg/dL, p< 0.001). In patients blindly assessed annually over a period of five years, it was found that the telemedicine group scored better than the standard care group on virtually all outcome measures at each annual evaluation. Mortality was not different between the groups, although power was limited [Shea S, 2009]. More recently, Charpentier et al., in a six-month multicenter study, enrolled 180 adult patients with type 1 diabetes on a basal-bolus insulin regimen, with baseline HbA1c ≥8%. Patients were randomized to either usual quarterly follow-up, or home use of a smartphone recommending insulin doses with quarterly visits, or use of the smartphone with short teleconsultations every two weeks but no visit until endpoint (Diabeo system). Use of the Diabeo system yielded a 0.91% decrease in HbA1c over controls and a 0.67% decrease in HbA1c when used without teleconsultation. There was no difference in the frequency of hypoglycemic episodes or in medical time spent for hospital or telephone consultations. However, patients using the Diabeo system spent nearly 5 h less than patients in other groups in attending hospital visits [Charpentier G, 2011]. Similarly, Bujnowska-Fedak et al enrolled a total of 100 adult patients with type 2 diabetes, divided between insulin- and non-insulin-requiring, in a randomized, controlled trial aimed at investigating the effects of telehome monitoring. The experimental group (n = 50) received an in-home wireless glucose monitor and transmitter, whereas the control group (n = 50) was instructed to follow the conventional arrangement. There was an overall reduction in HbA1c values in both experimental and control groups after 6 months. A significant difference in HbA1c values between the groups was observed only among the noninsulin-requiring patients. The experimental group reported considerably less hyperglycemic and hypoglycemic events. The profile of the patient who benefited the most from telemonitoring consisted of older, more educated patients, who had acquired the disease relatively recently, and who spent most of the time at home. The experimental group had higher overall scores on quality of life measures and sense of control over diabetes [Bujnowska-Fedak MM, 2011]. A recent meta-analysis of 22 trials and a total of 1,657 participants showed that mobile phone interventions for diabetes self-management reduced HbA1c values by a mean of 0.5% over a median of 6-month follow-up duration. Interestingly, type 2 diabetes patients reported significantly greater reductions in HbA1c than type 1 diabetes patients (0.8 vs. 0.3%; P = 0.02) [Liang X, 2011]. In conclusion, telemedicine case management intervention and tele-home care may potentially assist in daily diabetes management via the establishment of an active interaction between diabetic patients and healthcare professionals. However, further evidence is warranted, particularly when considering new innovative systems with a potential for implementation of patient's assistance and of diabetes drug therapy remotely.

We have recently developed a telemedicine system [Glucoonline®, 2011], which consists of a smartphone-connected glucometer, a software-implemented smartphone for real-time and anywhere BG data collection and transmission to a remote server, and a Decision Supported Software (DSS)-assisted server capable of performing data collection and analysis, and providing feed-back to the patient and the medical staff according to pre-defined specific algorithms. A pilot study showing the feasibility of using this system in 10 individuals with type 1 diabetes treated with a multiple daily injection (MDI) regimen over a 3-month period has been already carried out [Giorgino F, data on file]. We believe that this system could be now utilized in a prospective randomized controlled trial to investigate its suitability to enable improved glucose control in insulin-treated individuals with type 1 or type 2 diabetes mellitus.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 123
• Est. completion date: November 30, 2017
• Est. primary completion date: November 30, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• males and females

• age 18-70 yrs;

• insulin-treated diabetes (both type 1 and type 2 diabetes treated with at least 3 injections/day);

• diabetes diagnosis from at least 1 year;

• inadequate glycemic control (HbA1c ranging from 7.0% to 10.0%; local measurements within the last 6 weeks);

• ability and willingness to carry out SMBG;

• informed consent.

Exclusion Criteria:

• diagnosis of diabetes within less than 1 year;

• impending complications of diabetes: proliferative retinopathy or maculopathy (with significant loss of visual function), severe renal failure (eGFR <30), severe neuropathy (autonomic dysfunction, peripheral neuropathy, gastroparesis);

• clinically significant, active (over the past 12 months) disease of the cardiovascular, gastrointestinal, neurological, genito-urinary, haematological systems or severe uncontrolled hypertension (SBP >180 mmHg; DBP >100 mmHg);

• diagnosis of active neoplasia within the last 5 years (history of chemotherapy or radiation treated malignancy within 5 years prior to study procedure, except for lymphoma);

• pregnancy or intention to become pregnant during the study;

• poor compliance to study procedures.

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Procedure:
• Use of software-implemented glucometer for real-time collection and transmission of measured glucose values to remote server.
Device is a smartphone-connected glucometer. The smartphone will be implemented with a software for real-time collection and transmission of measured glucose values to the remote server. Thus, the glucometer will be made "hot" for real-time and anywhere data transmission. In addition, at the time of blood glucose measuring, the patient will enter information on whether the measurement is being performed in the pre-prandial, post-prandial or absorptive periods, and will indicate which meals the measurement refers to (i.e., breakfast, lunch, dinner, snack). SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS).
• Use of regular glucometer

Locations

Country	Name	City	State
Italy	University of Bari Aldo Moro	Bari	BA
Italy	University of Foggia	Foggia
Italy	IRCSS Casa Sollievo Sofferenza	San Giovanni Rotondo	FG

Sponsors (3)

Lead Sponsor	Collaborator
University of Bari	Eli Lilly and Company, LifeScan

Country where clinical trial is conducted

Italy, 

References & Publications (4)

Bujnowska-Fedak MM, Puchala E, Steciwko A. The impact of telehome care on health status and quality of life among patients with diabetes in a primary care setting in Poland. Telemed J E Health. 2011 Apr;17(3):153-63. doi: 10.1089/tmj.2010.0113. Epub 2011 Mar 5. — View Citation

Charpentier G, Benhamou PY, Dardari D, Clergeot A, Franc S, Schaepelynck-Belicar P, Catargi B, Melki V, Chaillous L, Farret A, Bosson JL, Penfornis A; TeleDiab Study Group. The Diabeo software enabling individualized insulin dose adjustments combined with telemedicine support improves HbA1c in poorly controlled type 1 diabetic patients: a 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study). Diabetes Care. 2011 Mar;34(3):533-9. doi: 10.2337/dc10-1259. Epub 2011 Jan 25. — View Citation

Liang X, Wang Q, Yang X, Cao J, Chen J, Mo X, Huang J, Wang L, Gu D. Effect of mobile phone intervention for diabetes on glycaemic control: a meta-analysis. Diabet Med. 2011 Apr;28(4):455-63. doi: 10.1111/j.1464-5491.2010.03180.x. — View Citation

Shea S, Weinstock RS, Teresi JA, Palmas W, Starren J, Cimino JJ, Lai AM, Field L, Morin PC, Goland R, Izquierdo RE, Ebner S, Silver S, Petkova E, Kong J, Eimicke JP; IDEATel Consortium. A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus: 5 year results of the IDEATel study. J Am Med Inform Assoc. 2009 Jul-Aug;16(4):446-56. doi: 10.1197/jamia.M3157. Epub 2009 Apr 23. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in HbA1c from baseline value		3-month, 6-month
Secondary	Changes in HbA1c from baseline value in relation to HbA1c value at baseline		6-month
Secondary	Percentages of patients with HbA1c >8.5% at 3 and 6 months		3-month, 6-month
Secondary	Percentages of patients with HbA1c <7.0% at 3 and 6 months		3-month, 6-month
Secondary	Percentages of patients with HbA1c <6.5% at 3 and 6 months		3-month, 6-month
Secondary	Differences in fasting blood glucose levels		3-month, 6-month
Secondary	Differences in blood glucose levels in the pre-prandial and post-prandial phases; meal-related glucose excursions (post/pre-meal "delta")		3-month, 6-month
Secondary	Frequency of hypoglycaemic episodes and relationship with changes in therapy		3-month, 6-month
Secondary	Changes in therapy (drug type and doses; in relation to SMBG values)		3-month, 6-month
Secondary	Appropriateness of glucose testing (% conformity based on recommended frequency of testing, also in relation to meals)		3-month, 6-month
Secondary	Indices of glucose variability (Kovatchev's LBGI, HBGI, ADRR)		3-month, 6-month
Secondary	Quality of life		6-month
Secondary	Proportion of subjects with eGFR less than 60 and high LBGI, HBGI, or ADRR indices		3-month, 6-month
Secondary	Subgroup analyses of changes in HbA1c from baseline according to patients' age (<45 yrs, >45yrs), type of diabetes (type 1, type 2), and diabetes duration (<5 yrs, >5 yrs)		6-month